scholarly journals Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Blood ◽  
2015 ◽  
Vol 126 (22) ◽  
pp. 2479-2483 ◽  
Author(s):  
Nicole Kucine ◽  
Sachie Marubayashi ◽  
Neha Bhagwat ◽  
Efthymia Papalexi ◽  
Priya Koppikar ◽  
...  
Keyword(s):  
Mouse Models ◽  
Therapeutic Efficacy ◽  
Therapeutic Approach ◽  
Hsp90 Inhibition ◽  
Key Points

Key Points PU-H71, a novel purine scaffold inhibitor, shows potent therapeutic efficacy in JAK-mutant ALL cells and mouse models. HSP90 inhibition retains therapeutic efficacy in ruxolitinib-persistent JAK-mutant ALL cells.

scholarly journals Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Blood ◽  
2016 ◽  
Vol 127 (9) ◽  
pp. 1117-1127 ◽  
Author(s):  
Joseph A. Fraietta ◽  
Kyle A. Beckwith ◽  
Prachi R. Patel ◽  
Marco Ruella ◽  
Zhaohui Zheng ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Mouse Models ◽  
Chimeric Antigen Receptor ◽  
Adoptive Immunotherapy ◽  
Therapeutic Efficacy ◽  
Car T Cells ◽  
Cell Engraftment ◽  
Key Points ◽  
Car T

Key Points Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.

scholarly journals Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2737-2748 ◽  
Author(s):  
Qingrong Huang ◽  
Shan He ◽  
Yuanyuan Tian ◽  
Yuting Gu ◽  
Pan Chen ◽  
...  
Keyword(s):  
T Cells ◽  
Protein Stability ◽  
Graft Versus Host Disease ◽  
Hsp90 Inhibition ◽  
Host Disease ◽  
Graft Versus Host ◽  
Alloreactive T Cells ◽  
Graft Versus Leukemia ◽  
Key Points ◽  
And Function

Key Points Ezh2 requires Hsp90 to maintain Ezh2 protein stability and function in alloreactive T cells. Pharmacological inhibition of Hsp90 destabilizes Ezh2 protein in alloreactive T cells and reduces GVHD but preserves graft-versus-leukemia effects.

scholarly journals AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer

2009 ◽  
Vol 8 (9) ◽  
pp. 2537-2545 ◽  
Author(s):  
Shu Yang ◽  
Van Chanh Ngo ◽  
Guo Bin Lew ◽  
Lih Wen Valerie Chong ◽  
Swee Shean Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mouse Models ◽  
Therapeutic Efficacy

scholarly journals Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2343-2354 ◽  
Author(s):  
Saar Gill ◽  
Sarah K. Tasian ◽  
Marco Ruella ◽  
Olga Shestova ◽  
Yong Li ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Myeloid Leukemia ◽  
Mouse Models ◽  
Chimeric Antigen Receptor ◽  
Myeloid Leukemia ◽  
Antigen Receptor ◽  
Key Points ◽  
Human Acute Myeloid Leukemia ◽  
Engineered T Cells ◽  
Acute Myeloid

Key Points Targeting of CD123 via CAR-engineered T cells results in rejection of human AML and myeloablation in mouse models.

scholarly journals Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models

2012 ◽  
Vol 5 (6) ◽  
pp. 852-859 ◽  
Author(s):  
J. J. Dowling ◽  
R. Joubert ◽  
S. E. Low ◽  
A. N. Durban ◽  
N. Messaddeq ◽  
...  
Keyword(s):  
Neuromuscular Junction ◽  
Mouse Models ◽  
Therapeutic Approach ◽  
Myotubular Myopathy ◽  
Novel Therapeutic

scholarly journals HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Blood ◽  
2016 ◽  
Vol 128 (21) ◽  
pp. 2517-2526 ◽  
Author(s):  
Caron Jacobson ◽  
Nadja Kopp ◽  
Jacob V. Layer ◽  
Robert A. Redd ◽  
Sebastian Tschuri ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Hsp90 Inhibitors ◽  
Hsp90 Inhibition ◽  
Key Points ◽  
Mantle Cell ◽  
Ibrutinib Resistance

Key Points Inhibition of HSP90 targets multiple dependences in mantle cell lymphoma. Clinically available HSP90 inhibitors overcome ibrutinib resistance in vitro and in vivo.

scholarly journals Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke

Blood ◽  
2015 ◽  
Vol 125 (8) ◽  
pp. 1325-1332 ◽  
Author(s):  
Tine Wyseure ◽  
Marina Rubio ◽  
Frederik Denorme ◽  
Sara Martinez de Lizarrondo ◽  
Miet Peeters ◽  
...  
Keyword(s):  
Mouse Models ◽  
Bleeding Time ◽  
Thrombolytic Treatment ◽  
Key Points ◽  
Pai 1

Key Points Early thrombolytic treatment with a bispecific inhibitor against TAFI and PAI-1 is effective without exogenous tPA. Even at the highest dose tested, the bispecific inhibitor against TAFI and PAI-1 does not prolong bleeding time.

scholarly journals Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria

Blood ◽  
2015 ◽  
Vol 126 (2) ◽  
pp. 257-261 ◽  
Author(s):  
Daniel N. Egan ◽  
Zhantao Yang ◽  
John Phillips ◽  
Janis L. Abkowitz
Keyword(s):  
Iron Deficiency ◽  
Therapeutic Approach ◽  
Erythroid Differentiation ◽  
Symptom Improvement ◽  
Iron Restriction ◽  
Key Points ◽  
Congenital Erythropoietic Porphyria ◽  
Novel Therapeutic ◽  
Marrow Cells

Key Points Iron deficiency results in symptom improvement in CEP and could be considered a novel therapeutic approach for this disease. CEP marrow cells demonstrated improved growth and erythroid differentiation in vitro under conditions of relative iron restriction.

Sign in / Sign up

Export Citation Format

Share Document